ZA201907755B - 5-5 fused rings as c5a inhibitors - Google Patents
5-5 fused rings as c5a inhibitorsInfo
- Publication number
- ZA201907755B ZA201907755B ZA2019/07755A ZA201907755A ZA201907755B ZA 201907755 B ZA201907755 B ZA 201907755B ZA 2019/07755 A ZA2019/07755 A ZA 2019/07755A ZA 201907755 A ZA201907755 A ZA 201907755A ZA 201907755 B ZA201907755 B ZA 201907755B
- Authority
- ZA
- South Africa
- Prior art keywords
- inhibitors
- fused rings
- fused
- rings
- Prior art date
Links
- 108010073240 complement C5a-inhibitors Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Liquid Crystal Substances (AREA)
- Glass Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Insulating Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513025P | 2017-05-31 | 2017-05-31 | |
| PCT/US2018/034908 WO2018222601A1 (en) | 2017-05-31 | 2018-05-29 | 5-5 FUSED RINGS AS C5a INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201907755B true ZA201907755B (en) | 2023-05-31 |
Family
ID=64455572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2019/07755A ZA201907755B (en) | 2017-05-31 | 2019-11-22 | 5-5 fused rings as c5a inhibitors |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US10683294B2 (enExample) |
| EP (1) | EP3630774B1 (enExample) |
| JP (1) | JP7141129B2 (enExample) |
| KR (1) | KR102586710B1 (enExample) |
| CN (1) | CN111032658B (enExample) |
| AR (1) | AR111841A1 (enExample) |
| AU (1) | AU2018277523B2 (enExample) |
| CA (1) | CA3064025A1 (enExample) |
| ES (1) | ES2934507T3 (enExample) |
| IL (1) | IL270842B2 (enExample) |
| MA (1) | MA48800A (enExample) |
| MX (1) | MX391392B (enExample) |
| TW (1) | TWI813570B (enExample) |
| WO (1) | WO2018222601A1 (enExample) |
| ZA (1) | ZA201907755B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111032658B (zh) | 2017-05-31 | 2022-12-20 | 凯莫森特里克斯股份有限公司 | 作为C5a抑制剂的5-5稠合环类 |
| JP7141130B2 (ja) | 2017-05-31 | 2022-09-22 | ケモセントリックス，インコーポレイティド | Ｃ５ａ阻害剤としての６－５融合環 |
| MA51331A (fr) | 2017-12-22 | 2020-10-28 | Chemocentryx Inc | COMPOSÉS CYCLIQUES CONDENSÉS 6,5 À SUBSTITUTION DIARYLE, UTILISÉS EN TANT QU'INHIBITEURS DU C5aR |
| SG11202005799XA (en) | 2017-12-22 | 2020-07-29 | Chemocentryx Inc | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
| BR112020019822A2 (pt) * | 2018-04-02 | 2021-03-16 | Chemocentryx, Inc. | Profármacos de antagonistas bicíclicos fundidos de c5ar |
| KR102890201B1 (ko) | 2019-07-10 | 2025-11-24 | 케모센트릭스, 인크. | Pd-l1 억제제로서의 인단 |
| CN112300169B (zh) * | 2019-07-26 | 2022-03-04 | 上海美迪西生物医药股份有限公司 | 吡咯并吡唑类衍生物、其制备方法及其在医药上的应用 |
| EP4045036A4 (en) | 2019-10-16 | 2023-11-15 | ChemoCentryx, Inc. | Heteroaryl-biphenyl amides for the treatment of pd-l1 diseases |
| CR20220216A (es) | 2019-10-16 | 2023-01-09 | Chemocentryx Inc | Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1 |
| JP2023542789A (ja) * | 2020-09-28 | 2023-10-12 | シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド | ピラゾール化合物並びにその調製方法及び使用 |
| JP2023548117A (ja) | 2020-10-28 | 2023-11-15 | ケモセントリックス， インコーポレイテッド | 化膿性汗腺炎を処置する方法 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001287654B2 (en) | 2000-08-10 | 2006-12-14 | Pfizer Italia S.R.I. | Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| CN1454086A (zh) | 2000-09-29 | 2003-11-05 | 神经能质公司 | 高亲和性小分子C5a受体调节物 |
| SE524438C2 (sv) | 2000-10-05 | 2004-08-10 | Magnus Georg Goertz | Fjärrstyrt dörrelaterat låsarrangemang, första och andra datorpogramprodukt, bärande medium och ett datorlösbart medium |
| EP1396493A4 (en) | 2001-04-26 | 2005-08-03 | Ajinomoto Kk | HETEROCYCLIC COMPOUNDS |
| ITMI20012025A1 (it) | 2001-09-28 | 2003-03-28 | Dompe Spa | Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono |
| JP2006508894A (ja) | 2002-03-28 | 2006-03-16 | ニューロジェン・コーポレーション | Ｃ５ａ受容体調節因子としての置換テトラヒドロイソキノリン |
| EP1487796A4 (en) | 2002-03-28 | 2005-11-16 | Neurogen Corp | SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR |
| CA2480082A1 (en) | 2002-03-29 | 2003-10-16 | Neurogen Corporation | Combination therapy for the treatment of conditions with pathogenic inflammatory components |
| WO2004016592A1 (en) | 2002-08-14 | 2004-02-26 | Ppd Discovery, Inc. | Prenylation inhibitors and methods of their synthesis and use |
| US7169775B2 (en) | 2002-08-21 | 2007-01-30 | Neurogen Corporation | Amino methyl imidazoles as C5a receptor modulators |
| AU2003291403A1 (en) | 2002-11-08 | 2004-06-03 | Neurogen Corporation | 3-substituted-6-aryl pyridined as ligands of c5a receptors |
| US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
| US20040214856A1 (en) | 2003-04-23 | 2004-10-28 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
| AU2003902354A0 (en) | 2003-05-15 | 2003-05-29 | Harkin, Denis W. | Treatment of haemorrhagic shock |
| WO2005007087A2 (en) | 2003-07-03 | 2005-01-27 | Neurogen Corporation | Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators |
| US7906528B2 (en) * | 2004-10-05 | 2011-03-15 | Novartis International Pharmaceutical Ltd. | Pyrrolo-pyridine, pyrrolo-pyrimidine and related heterocyclic compounds |
| US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
| US20070112015A1 (en) * | 2005-10-28 | 2007-05-17 | Chemocentryx, Inc. | Substituted dihydropyridines and methods of use |
| KR20110031475A (ko) | 2008-06-20 | 2011-03-28 | 제넨테크, 인크. | 트리아졸로피리딘 ｊａｋ 억제제 화합물 및 방법 |
| US20110275639A1 (en) | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| EP3508477B1 (en) | 2008-12-22 | 2021-11-10 | ChemoCentryx, Inc. | C5ar antagonists |
| DK2585064T3 (en) | 2010-06-24 | 2017-07-24 | Chemocentryx Inc | C5aR antagonists |
| US8846656B2 (en) | 2011-07-22 | 2014-09-30 | Novartis Ag | Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators |
| KR20150042271A (ko) | 2012-08-16 | 2015-04-20 | 얀센 파마슈티카 엔.브이. | N형 칼슘 채널 차단제로서의 치환된 피롤로피라졸 |
| CN103421006B (zh) | 2013-08-18 | 2016-06-22 | 上海师范大学 | 2,3,5,7-四取代二氢吡唑并六氢吡啶衍生物及其制备方法和应用 |
| GB201321746D0 (en) | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
| WO2017176620A2 (en) | 2016-04-04 | 2017-10-12 | Chemocentryx, Inc. | SOLUBLE C5aR ANTAGONISTS |
| JP7141130B2 (ja) | 2017-05-31 | 2022-09-22 | ケモセントリックス，インコーポレイティド | Ｃ５ａ阻害剤としての６－５融合環 |
| CN111032658B (zh) | 2017-05-31 | 2022-12-20 | 凯莫森特里克斯股份有限公司 | 作为C5a抑制剂的5-5稠合环类 |
| SG11202005799XA (en) | 2017-12-22 | 2020-07-29 | Chemocentryx Inc | DIARYL SUBSTITUTED 5,5-FUSED RING COMPOUNDS AS C5aR INHIBITORS |
| MA51331A (fr) | 2017-12-22 | 2020-10-28 | Chemocentryx Inc | COMPOSÉS CYCLIQUES CONDENSÉS 6,5 À SUBSTITUTION DIARYLE, UTILISÉS EN TANT QU'INHIBITEURS DU C5aR |
| BR112020019822A2 (pt) | 2018-04-02 | 2021-03-16 | Chemocentryx, Inc. | Profármacos de antagonistas bicíclicos fundidos de c5ar |
-
2018
- 2018-05-29 CN CN201880036650.8A patent/CN111032658B/zh active Active
- 2018-05-29 WO PCT/US2018/034908 patent/WO2018222601A1/en not_active Ceased
- 2018-05-29 MX MX2019014292A patent/MX391392B/es unknown
- 2018-05-29 ES ES18809125T patent/ES2934507T3/es active Active
- 2018-05-29 MA MA048800A patent/MA48800A/fr unknown
- 2018-05-29 KR KR1020197038670A patent/KR102586710B1/ko active Active
- 2018-05-29 CA CA3064025A patent/CA3064025A1/en active Pending
- 2018-05-29 JP JP2019565826A patent/JP7141129B2/ja active Active
- 2018-05-29 US US15/991,747 patent/US10683294B2/en active Active
- 2018-05-29 EP EP18809125.0A patent/EP3630774B1/en active Active
- 2018-05-29 AU AU2018277523A patent/AU2018277523B2/en active Active
- 2018-05-31 AR ARP180101445A patent/AR111841A1/es unknown
- 2018-05-31 TW TW107118603A patent/TWI813570B/zh active
-
2019
- 2019-11-21 IL IL270842A patent/IL270842B2/en unknown
- 2019-11-22 ZA ZA2019/07755A patent/ZA201907755B/en unknown
-
2020
- 2020-05-04 US US16/865,648 patent/US11479553B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AR111841A1 (es) | 2019-08-21 |
| US10683294B2 (en) | 2020-06-16 |
| CA3064025A1 (en) | 2018-12-06 |
| MA48800A (fr) | 2020-04-08 |
| TWI813570B (zh) | 2023-09-01 |
| CN111032658A (zh) | 2020-04-17 |
| AU2018277523B2 (en) | 2022-06-23 |
| CN111032658B (zh) | 2022-12-20 |
| TW201902897A (zh) | 2019-01-16 |
| EP3630774A1 (en) | 2020-04-08 |
| JP7141129B2 (ja) | 2022-09-22 |
| US20210009594A1 (en) | 2021-01-14 |
| RU2019142985A (ru) | 2021-06-30 |
| AU2018277523A1 (en) | 2019-12-05 |
| EP3630774A4 (en) | 2020-10-07 |
| KR20200013720A (ko) | 2020-02-07 |
| US20180346471A1 (en) | 2018-12-06 |
| MX2019014292A (es) | 2022-04-07 |
| MX391392B (es) | 2025-03-21 |
| EP3630774B1 (en) | 2022-11-23 |
| JP2020522483A (ja) | 2020-07-30 |
| US11479553B2 (en) | 2022-10-25 |
| WO2018222601A1 (en) | 2018-12-06 |
| ES2934507T3 (es) | 2023-02-22 |
| IL270842B1 (en) | 2023-01-01 |
| BR112019025230A2 (pt) | 2020-06-16 |
| IL270842A (en) | 2020-01-30 |
| IL270842B2 (en) | 2023-05-01 |
| KR102586710B1 (ko) | 2023-10-10 |
| RU2019142985A3 (enExample) | 2021-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201907755B (en) | 5-5 fused rings as c5a inhibitors | |
| IL270828A (en) | 6-5 fused ring as C5a inhibitors | |
| ZA201905618B (en) | Fused imidazo-piperidine jak inhibitors | |
| IL249261A0 (en) | Implications of a compressed dihydropyrimido ring as an hbv inhibitor | |
| PL3601283T3 (pl) | Związek będący skondensowanym imidazo-piperydynowym inhibitorem JAK | |
| AU365267S (en) | Ring | |
| TWD174460S (zh) | 戒指 | |
| TWD174457S (zh) | 戒指 | |
| AU363632S (en) | Pendant | |
| PL3279187T3 (pl) | Pochodna z 9-członowym skondensowanym pierścieniem | |
| AU201812941S (en) | Ring Protector | |
| IL269409A (en) | Combinations of chk1- and wee1 - inhibitors | |
| PL3289248T3 (pl) | Pierścienie uszczelniające | |
| SG11201706941WA (en) | Improved metal seal ring | |
| GB201603056D0 (en) | Ring clip | |
| GB201512682D0 (en) | Joint stabilisation | |
| IL253322A0 (en) | bace1 inhibitors | |
| IL274496A (en) | macro carrier | |
| SG10202003176WA (en) | Ring assembly | |
| PL3311060T3 (pl) | Nośnik rury | |
| SI3243016T1 (sl) | Tesnilni obroč | |
| GB201619513D0 (en) | 2-par clamp ring method | |
| AU201812909S (en) | Ring | |
| GB201720326D0 (en) | Nimb Ring | |
| AU201715227S (en) | Ring |